Download the Agenda


Speaker Information

Dr Geert Mudde
Dr Geert Mudde Founder and CSO OncoQR ML
Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions such as “Deputy Head of the Immunology Department” at the Novartis Research Institute in Vienna, Austria, “Director of Allergy and Inflammation/Immunology” at the Parke Davis Research Institute in Fresnes, France, “Director Immunology” at Ingenium Pharmaceuticals, Martinsried, Germany, and “VP Exploratory Research” at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim “Director Discovery Research”. Dr. Mudde (co-)founded f-star GmbH in 2006 and is founder and serves as CSO of S-TARget therapeutics GmbH (2009) as well as OncoQR ML GmbH which was founded in 2013


Main Conference Day 1

3:50 PM Next Generation Checkpoint Control: Tumor Specific Polyclonal Humoral and Cellular Immune Responses

•         How to rapidly induce strong polyclonal clinically relevant anti-tumor responses
•         Understand why successful active immunization is better than current (blockbuster) monoclonal antibody therapy
•         Antigen specific checkpoint control; turning the switch on and off at will
•         Learn about a human specific vaccine technology platform

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!

IDGA

Become a Pharma IQ Member and receive our weekly newsletter!